Vestmark Advisory Solutions Inc. Takes $567,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY

Vestmark Advisory Solutions Inc. purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,740 shares of the biopharmaceutical company’s stock, valued at approximately $567,000.

A number of other large investors also recently bought and sold shares of ALNY. Vanguard Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock valued at $3,525,544,000 after acquiring an additional 323,206 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 0.8% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock worth $1,192,988,000 after acquiring an additional 33,696 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock worth $946,466,000 after purchasing an additional 185,783 shares during the period. American Century Companies Inc. boosted its position in shares of Alnylam Pharmaceuticals by 9.8% during the 1st quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company’s stock worth $475,353,000 after purchasing an additional 156,411 shares during the period. Finally, Orbis Allan Gray Ltd increased its holdings in Alnylam Pharmaceuticals by 11.0% in the 1st quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company’s stock valued at $441,462,000 after purchasing an additional 162,121 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 2.3%

Shares of NASDAQ ALNY opened at $451.95 on Wednesday. The business has a 50-day moving average of $458.75 and a two-hundred day moving average of $380.73. The company has a market capitalization of $59.71 billion, a price-to-earnings ratio of -182.98 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $1.51. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $1.25 billion for the quarter, compared to the consensus estimate of $943.37 million. During the same quarter in the prior year, the business posted ($0.50) EPS. The business’s revenue for the quarter was up 149.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,924 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at approximately $29,568,138.45. This trade represents a 12.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Dennis A. Ausiello sold 31,448 shares of the business’s stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the sale, the director owned 911 shares of the company’s stock, valued at $397,724.38. This represents a 97.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 98,144 shares of company stock valued at $44,160,261 over the last three months. 1.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have commented on ALNY. Scotiabank upped their price target on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a “sector outperform” rating in a research note on Friday, August 1st. BMO Capital Markets increased their target price on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. The Goldman Sachs Group raised their target price on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a report on Tuesday, September 16th. Citigroup boosted their price target on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Finally, Morgan Stanley raised their price objective on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research note on Monday, October 6th. Twenty-three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $482.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.